ホーム>>Signaling Pathways>> GPCR/G protein>> Adrenergic Receptor>>Naftopidil (hydrochloride)

Naftopidil (hydrochloride) (Synonyms: KT-611 hydrochloride; BM-15275 hydrochloride)

カタログ番号GC44311

ナフトピジル (塩酸塩) (KT-611 塩酸塩) は選択的アルファ 1 アドレナリン受容体アンタゴニストであり、クローン化されたヒト α1a-、α1b-、および α1d-アドレナリン受容体サブタイプに対してそれぞれ 3.7 nM、20 nM、および 1.2 nM の Kis を持ちます。ナフトピジル(塩酸塩)には抗増殖作用があります。ナフトピジル (塩酸塩) は、前立腺肥大症の研究に使用できます。

Products are for research use only. Not for human use. We do not sell to patients.

Naftopidil (hydrochloride) 化学構造

Cas No.: 1164469-60-6

サイズ 価格 在庫数 個数
25mg
$67.00
在庫あり
50mg
$127.00
在庫あり
100mg
$240.00
在庫あり
250mg
$535.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Naftopidil is an α1-adrenergic receptor antagonist that competitively inhibits α-adrenoceptor-mediated contractions induced by noradrenaline with pA2 values of 6.73-8.15 in various blood vessels from dog, rabbit, guinea pig, and rat. It binds to the cloned human α1-adrenergic receptors with Ki values of 3.7, 20, and 1.2 nM for α1A, α1B and α1D, respectively. Clinical formulations of naftopidil are used in the treatment of benign prostatic hyperplasia in Japan. Naftopidil also exhibits antiproliferative activity, inhibiting the growth of androgen-sensitive LNcaP cells and androgen-insensitive PC-3 cancer cell lines with IC50 values of 22.2 and 33.2 µM, respectively.

レビュー

Review for Naftopidil (hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Naftopidil (hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.